NR1H3 and Hepatic fibrosis: Consistent with the hepatoprotective effects of LXRα being exerted directly in hepatocytes, treatment with an LXRα expressing virus normalized body weight (Extended Data Fig. 8a) and prevented liver injury and hepatic fibrosis (Fig. 5b,c,g,h) despite adverse effects on serum triglycerides (Fig. 5d) and restoration of hepatic steatosis (Fig. 5g).